Novartis Ag Adr Stock Price To Earnings To Growth

NVS Stock

USD 117.73 0.10 0.08%

Fundamental analysis of Novartis allows traders to better anticipate movements in Novartis' stock price by examining its financial health and performance throughout various phases of its business cycle.

Short Long Term Debt Total Total Assets

Build AI portfolio with Novartis Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novartis AG ADR Company Price To Earnings To Growth Analysis

Novartis' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Novartis Price To Earnings To Growth

1.26 X

Most of Novartis' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novartis Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Intangible Assets	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.91	0.52	0.66	0.92	0.92	0.72	-0.01	0.86	0.41	0.02	0.55	0.02	0.93	0.7	0.98	-0.1	0.85	0.14	0.37	0.3	-0.35	0.23	0.05	0.3	0.13
Total Stockholder Equity	0.91		0.63	0.35	0.99	0.81	0.81	-0.06	0.57	0.25	0.25	0.31	0.25	0.75	0.38	0.9	-0.36	0.93	0.47	0.24	0.45	-0.24	-0.1	-0.16	0.52	0.27
Current Deferred Revenue	0.52	0.63		0.1	0.68	0.36	0.24	-0.26	0.25	0.04	0.12	0.2	0.12	0.34	0.26	0.48	-0.28	0.46	0.47	0.22	0.48	-0.71	-0.13	-0.09	0.31	0.12
Net Debt	0.66	0.35	0.1		0.39	0.58	0.26	0.11	0.87	0.22	-0.31	0.66	-0.31	0.83	0.91	0.65	0.22	0.3	-0.47	0.37	0.08	-0.3	0.67	0.16	-0.11	-0.16
Retained Earnings	0.92	0.99	0.68	0.39		0.81	0.76	-0.04	0.6	0.28	0.21	0.33	0.21	0.77	0.44	0.9	-0.31	0.89	0.45	0.28	0.44	-0.33	-0.06	-0.11	0.48	0.29
Accounts Payable	0.92	0.81	0.36	0.58	0.81		0.79	-0.02	0.83	0.43	-0.06	0.45	-0.06	0.87	0.62	0.94	-0.07	0.83	0.01	0.18	0.12	-0.27	0.13	0.07	0.11	0.1
Net Receivables	0.72	0.81	0.24	0.26	0.76	0.79		-0.23	0.44	0.03	0.25	0.16	0.25	0.62	0.16	0.79	-0.45	0.93	0.33	-0.13	0.3	0.16	-0.29	-0.3	0.34	0.03
Short Term Investments	-0.01	-0.06	-0.26	0.11	-0.04	-0.02	-0.23		0.06	0.67	-0.11	-0.19	-0.11	0.07	0.14	-0.04	0.2	-0.27	-0.16	0.06	-0.48	-0.02	0.27	0.08	0.01	0.77
Total Liab	0.86	0.57	0.25	0.87	0.6	0.83	0.44	0.06		0.49	-0.27	0.7	-0.27	0.91	0.92	0.84	0.23	0.54	-0.3	0.43	0.05	-0.39	0.58	0.28	-0.04	-0.07
Total Current Assets	0.41	0.25	0.04	0.22	0.28	0.43	0.03	0.67	0.49		-0.33	0.12	-0.33	0.36	0.47	0.36	0.34	0.11	-0.14	0.35	-0.51	-0.34	0.43	0.41	-0.1	0.55
Capital Stock	0.02	0.25	0.12	-0.31	0.21	-0.06	0.25	-0.11	-0.27	-0.33		-0.25	1.0	-0.14	-0.43	-0.01	-0.79	0.25	0.74	-0.31	0.73	0.44	-0.66	-0.67	0.88	0.19
Short Term Debt	0.55	0.31	0.2	0.66	0.33	0.45	0.16	-0.19	0.7	0.12	-0.25		-0.25	0.65	0.61	0.5	0.37	0.27	-0.29	0.55	0.11	-0.26	0.44	0.31	-0.01	-0.38
Common Stock	0.02	0.25	0.12	-0.31	0.21	-0.06	0.25	-0.11	-0.27	-0.33	1.0	-0.25		-0.14	-0.43	-0.01	-0.79	0.25	0.74	-0.31	0.73	0.44	-0.66	-0.67	0.88	0.19
Intangible Assets	0.93	0.75	0.34	0.83	0.77	0.87	0.62	0.07	0.91	0.36	-0.14	0.65	-0.14		0.81	0.93	0.05	0.67	-0.1	0.43	0.14	-0.31	0.36	0.18	0.12	0.09
Long Term Debt	0.7	0.38	0.26	0.91	0.44	0.62	0.16	0.14	0.92	0.47	-0.43	0.61	-0.43	0.81		0.67	0.37	0.28	-0.4	0.51	-0.03	-0.53	0.74	0.41	-0.19	-0.02
Good Will	0.98	0.9	0.48	0.65	0.9	0.94	0.79	-0.04	0.84	0.36	-0.01	0.5	-0.01	0.93	0.67		-0.15	0.86	0.14	0.31	0.24	-0.28	0.15	0.02	0.25	0.12
Treasury Stock	-0.1	-0.36	-0.28	0.22	-0.31	-0.07	-0.45	0.2	0.23	0.34	-0.79	0.37	-0.79	0.05	0.37	-0.15		-0.39	-0.66	0.38	-0.58	-0.26	0.66	0.76	-0.64	-0.12
Property Plant Equipment	0.85	0.93	0.46	0.3	0.89	0.83	0.93	-0.27	0.54	0.11	0.25	0.27	0.25	0.67	0.28	0.86	-0.39		0.39	0.06	0.45	-0.06	-0.15	-0.24	0.42	0.01
Net Tangible Assets	0.14	0.47	0.47	-0.47	0.45	0.01	0.33	-0.16	-0.3	-0.14	0.74	-0.29	0.74	-0.1	-0.4	0.14	-0.66	0.39		0.01	0.57	0.2	-0.69	-0.32	0.81	0.41
Deferred Long Term Liab	0.37	0.24	0.22	0.37	0.28	0.18	-0.13	0.06	0.43	0.35	-0.31	0.55	-0.31	0.43	0.51	0.31	0.38	0.06	0.01		-0.05	-0.27	0.51	0.67	0.04	0.06
Long Term Investments	0.3	0.45	0.48	0.08	0.44	0.12	0.3	-0.48	0.05	-0.51	0.73	0.11	0.73	0.14	-0.03	0.24	-0.58	0.45	0.57	-0.05		0.04	-0.32	-0.51	0.72	-0.18
Short Long Term Debt	-0.35	-0.24	-0.71	-0.3	-0.33	-0.27	0.16	-0.02	-0.39	-0.34	0.44	-0.26	0.44	-0.31	-0.53	-0.28	-0.26	-0.06	0.2	-0.27	0.04		-0.38	-0.27	0.31	-0.05
Long Term Debt Total	0.23	-0.1	-0.13	0.67	-0.06	0.13	-0.29	0.27	0.58	0.43	-0.66	0.44	-0.66	0.36	0.74	0.15	0.66	-0.15	-0.69	0.51	-0.32	-0.38		0.53	-0.45	-0.18
Cash And Equivalents	0.05	-0.16	-0.09	0.16	-0.11	0.07	-0.3	0.08	0.28	0.41	-0.67	0.31	-0.67	0.18	0.41	0.02	0.76	-0.24	-0.32	0.67	-0.51	-0.27	0.53		-0.49	0.06
Net Invested Capital	0.3	0.52	0.31	-0.11	0.48	0.11	0.34	0.01	-0.04	-0.1	0.88	-0.01	0.88	0.12	-0.19	0.25	-0.64	0.42	0.81	0.04	0.72	0.31	-0.45	-0.49		0.33
Net Working Capital	0.13	0.27	0.12	-0.16	0.29	0.1	0.03	0.77	-0.07	0.55	0.19	-0.38	0.19	0.09	-0.02	0.12	-0.12	0.01	0.41	0.06	-0.18	-0.05	-0.18	0.06	0.33

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Novartis

Novartis Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.94)

At this time, Novartis' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Novartis AG ADR has a Price To Earnings To Growth of 1.2556 times. This is 76.85% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 74.32% higher than that of the company.

Novartis Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.

Novartis is currently under evaluation in price to earnings to growth category among its peers.

Novartis ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novartis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novartis' managers, analysts, and investors.

Environmental

Governance

Social

Novartis Fundamentals

	Return On Equity	0.32
	Return On Asset	0.12
	Profit Margin	0.25 %
	Operating Margin	0.37 %
	Current Valuation	253.26 B
	Shares Outstanding	1.94 B
	Shares Owned By Institutions	7.26 %
	Number Of Shares Shorted	4.25 M
	Price To Earning	9.22 X
	Price To Book	5.32 X
	Price To Sales	4.13 X
	Revenue	51.72 B
	Gross Profit	42.1 B
	EBITDA	20.71 B
	Net Income	11.94 B
	Cash And Equivalents	8.87 B
	Cash Per Share	8.84 X
	Total Debt	31.26 B
	Debt To Equity	0.47 %
	Current Ratio	1.31 X
	Book Value Per Share	21.69 X
	Cash Flow From Operations	17.62 B
	Short Ratio	2.94 X
	Earnings Per Share	7.01 X
	Price To Earnings To Growth	1.26 X
	Target Price	116.85
	Number Of Employees	75.88 K
	Beta	0.55
	Market Capitalization	228.1 B
	Total Asset	102.25 B
	Retained Earnings	46.56 B
	Working Capital	1.01 B
	Current Asset	22.84 B
	Current Liabilities	23.71 B
	Annual Yield	0.03 %
	Five Year Return	3.53 %
	Net Asset	102.25 B
	Last Dividend Paid	3.86

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC